Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1669489

registered interest
date	13/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Neurodiversity: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people were diagnosed with (a) autism, (b) ADHD and (c) dyslexia in the East of England in the last five years.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	1733
answer	answer is ministerial correction date of answer 21/11/2023 answer text <p>The information requested is not held centrally but may be held locally by individual National Health Service trusts or commissioners.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 21/11/2023 11:28:22 answering member 4492 label Biography information for Maria Caulfield
tabling member	4784 label Biography information for Duncan Baker

1490462

registered interest
date	19/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Homes: Staff
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support care home workers.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	901166
answer	answer is ministerial correction date of answer 19/07/2022 answer text <p>I would like to recognise the enormous contribution care home workers, and all the care workforce, make to this country.</p><p>In our People at the Heart of Care White Paper<em>, </em>we set out a landmark investment of £500 million to develop and support the workforce.</p><p>This a five-fold increase in public spending on workforce training, creating hundreds of thousands of training places with clear pathways for development and progression.</p><p>These measures will make a real difference to the support that care workers get to develop and progress their career.</p> answering member constituency Chichester answering member printed Gillian Keegan question first answered 19/07/2022 15:52:30 answering member 4680 label Biography information for Gillian Keegan
tabling member	4784 label Biography information for Duncan Baker

1452143

registered interest
date	17/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December 2021 to Question 92097 and following the Conditional Marketing Authorisation awarded by the Medicines and Healthcare products Regulatory Agency on 17 March 2022, what plans he has to ensure that severely immunocompromised patients have access to Evusheld; and what estimate he has made of when the first patients will start to receive that treatment.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	142089
answer	answer is ministerial correction date of answer 24/03/2022 answer text <p>We are unable to provide the information requested as it is commercially sensitive. Any public announcement on the procurement of treatments would be made after an agreement is reached with companies. The Department is scoping the potential introduction of pre-exposure prophylaxis. This includes identification of the most appropriate patient groups which could benefit and the potential deployment and administration process. However, treatments must be clinically cost-effective and demonstrate sufficient efficacy against Omicron and new variants.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 24/03/2022 16:51:12 answering member 4447 label Biography information for Maggie Throup
tabling member	4784 label Biography information for Duncan Baker

1399405

registered interest
date	04/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Protective Clothing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, for what reason the Government does not recommend (a) FFP2 and (b) FFP3 face masks as offering additional protection to the wearer against covid-19.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	97144
answer	answer is ministerial correction date of answer 02/03/2022 answer text <p>The Health and Safety Executive does not recommend the routine use of FFP2 masks in clinical practice as these are of lower efficacy than FFP3 masks. FFP3 masks are recommended for use in some health and care settings. Infection prevention and control guidance for staff in all health and care settings states that FFP3 masks should be worn by staff caring for patients where a risk assessment indicates the need.</p><p>FFP3 masks and other higher specification personal protective equipment must be professionally fit tested to ensure that air flows through the filter rather than around the mask. If these masks are provided without fit testing, it is not clear that they will be effective. Additionally, it may be difficult for members of the public to safely and comfortably wear a fitted mask for extended periods of time. Face coverings are no longer mandated by law.</p><p><em> </em></p> answering member constituency Erewash answering member printed Maggie Throup question first answered 02/03/2022 09:52:27 answering member 4447 label Biography information for Maggie Throup
tabling member	4784 label Biography information for Duncan Baker

1388172

registered interest
date	15/12/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 14 December 2021 to Question 89686 on Coronavirus: Vaccination, when 16-17 year olds with chronic asthma in group 6 will be (a) eligible and (b) prioritised for a covid-19 booster vaccination; and whether he will use the flu jab list as a basis for efficiently identifying those who need to be prioritised for any future covid-19 booster vaccinations.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	93909
answer	answer is ministerial correction date of answer 31/01/2022 answer text <p>The Government accepted advice from the Joint Committee on Vaccination and Immunisation (JCVI) that those aged 16 to 49 years old with underlying health conditions which put them at higher risk of severe COVID-19 should be offered a booster vaccine. This included individuals with 'poorly controlled asthma', defined as:</p><p>- Receiving two or more courses of oral corticosteroids in the preceding 24 months;</p><p>- Being on maintenance oral corticosteroids; and</p><p>- Having one or more hospital admission(s) for asthma in the preceding 24 months.</p><p>The flu clinical risk groups were initially considered as a potential way to identify and prioritise individuals at risk of COVID-19. However, when evaluating the data, the JCVI found that, although there was some overlap between the influenza clinical risk groups and those at high risk of severe COVID-19, there were some differences. At this stage no decision has been made about who will be prioritised for any for any future booster vaccinations, and whether the flu clinical risk groups will be used as part of the considerations.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 31/01/2022 15:45:21 answering member 4447 label Biography information for Maggie Throup previous answer version 42115 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
tabling member	4784 label Biography information for Duncan Baker

1387284

registered interest
date	13/12/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the AstraZeneca drug Evusheld for immunosuppressed people in the UK; what plans he has to use that drug as a (a) prophylactic and (b) treatment; and what his timeline is for the rollout of that drug for use in the UK.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	92097
answer	answer is ministerial correction date of answer 20/12/2021 answer text <p>We continue to monitor the emerging data for AstraZeneca’s long-acting antibody therapy, AZD7442, also known as Evusheld. AstraZeneca have discussed potential approvals with the Medicines and Healthcare products Regulatory Agency .</p><p>The Department published a Prior information Notice (PIN) on 5 October 2021 inviting suppliers to submit an expression of interest on neutralising antibody treatments being developed for treating and preventing COVID-19. The PIN is accessible by suppliers and enables the Department to undertake a fair and transparent market engagement process with suppliers. We are unable to provide further information on the deployment of Evusheld as it is commercially sensitive.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 20/12/2021 12:14:28 answering member 4447 label Biography information for Maggie Throup previous answer version 39905 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
tabling member	4784 label Biography information for Duncan Baker

1386250

registered interest
date	08/12/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to prioritise those under 40 who were vaccinated for covid-19 as part of group 6 previously part of the booster roll out programme; when he expects 16-17 years old in group 6 to be (a) eligible and (b) prioritised for a booster, including chronic asthmatics; what assurances his Department plans to provide those groups; and if his Department will use the flu jab list as a basis for identifying those who need to be prioritised for covid-19 booster vaccinations.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	89686
answer	answer is ministerial correction date of answer 14/12/2021 answer text <p><strong></strong>On 29 November 2021 the Government accepted advice from the Joint Committee on Vaccination and Immunisation (JCVI) to accelerate the COVID-19 booster vaccination programme. All adults over 18 years old are now eligible for a booster dose, which will be given no sooner than three months after completion of the primary course.</p><p>The flu clinical risk groups were initially considered as a potential way to identify and prioritise individuals at risk of COVID-19. However, when evaluating the data, the JCVI found that, although there was some overlap between the influenza clinical risk groups and those at high risk of severe COVID-19, there were some differences.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 14/12/2021 12:09:41 answering member 4447 label Biography information for Maggie Throup previous answer version 38778 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
tabling member	4784 label Biography information for Duncan Baker

1352544

registered interest
date	03/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the findings of (a) the ONS that chronic lower respiratory disease is the third most common underlying condition with death as a result of covid-19 in quarter 2 of 2021 and (b) of the British Lung Foundation, in its 2012 survey, that 81 per cent of chronic lower respiratory disease is asthma, if he will make it his policy that people with asthma who receive a free annual flu vaccination will be included in any covid-19 booster vaccination programme.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	42174
answer	answer is ministerial correction date of answer 08/09/2021 answer text <p>The Joint Committee on Vaccination and Immunisation’s (JCVI) interim advice is that COVID-19 booster vaccinations should first be offered to the most vulnerable. The JCVI advises a two stage approach, with individuals in stage one offered a booster vaccine and flu vaccine, as soon as possible from September. Individuals in stage two would be offered a booster vaccine as soon as practicable after stage one, with equal emphasis on deployment of the flu vaccine where eligible. The JCVI suggests those aged 16 to 49 years old who are in an influenza or COVID-19 at risk group, including some patients with chronic respiratory disease and asthma are currently included in stage two.</p><p>Final decisions on the timing and scope and cohort eligibility, booster programme will be confirmed once the JCVI has provided their final advice.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 41664 question first answered 08/09/2021 15:14:11 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4784 label Biography information for Duncan Baker

1349536

registered interest
date	22/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Travel: Quarantine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will (a) clarify the rationale and (b) make available the data that informed the decision for people returning from France regardless of vaccination status to quarantine for 10 days in the UK from 19 July 2021.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	38425
answer	answer is ministerial correction date of answer 11/10/2021 answer text <p>As of 19 July, GISAID data showed there have been to date 2,959 cases of the Beta variant in France or 5.2% of all cases, compared to 1,052 cases of the Beta variant in the United Kingdom or 0.2% of all cases, 44 cases or 0.5% of all cases in Greece and 621 cases or 1.4% of all cases in Spain since the start of the pandemic. As of 14 July, more sequences uploaded to the GISAID international database in the last three to four months were attributed to the Beta variant in France, than in Spain or Greece. The precautionary measure of the current quarantine rules and testing for travellers into the UK from France was meant to significantly reduce the risk of importing cases of the Beta variant, preventing community clusters or outbreaks.</p><p>From 8 August, arrivals from and those who have transited through France in the last ten days who have been fully vaccinated under the UK vaccination programme approved by the Medicines and Healthcare products Regulatory Agency do not need to quarantine. They are still expected to take a day two test.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 11/10/2021 14:09:31 answering member 4447 label Biography information for Maggie Throup previous answer version 18921 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380
tabling member	4784 label Biography information for Duncan Baker

1339447

registered interest
date	23/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of (a) using the existing 2020-21 flu vaccination list for all future covid-19 booster vaccines and (b) the potential merits of using that list to protect all vulnerable people, including those with asthma who take daily Inhaled steroids.
tabling member constituency	North Norfolk
tabling member printed	Duncan Baker
uin	21346
answer	answer is ministerial correction date of answer 28/06/2021 answer text <p>We are preparing for a potential booster vaccination programme from the autumn. Whilst we are planning for several potential scenarios, final decisions on the timing and scope of the booster programme will not be taken until later this year, in line with results from key clinical studies and independent advice from the Joint Committee for Vaccination and Immunisation (JCVI). The JCVI will review the emerging scientific evidence from studies on co-administering the flu and COVID-19 vaccines safely, alongside data supplied by manufacturers, to inform the Government in the decision-making process.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 28/06/2021 13:34:09 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4784 label Biography information for Duncan Baker